2 hours ago2 hr Executive Summary and Clinical ContextFor nearly two decades, neonatal and obstetric clinical guidance regarding maternal analgesia was defined by an absolute prohibition: codeine is contraindicated during breastfeeding. Driven by warnings from the US Food and Drug Administration (FDA), European Medicines Agency (EMA), and health agencies worldwide, this dogma originated from a single 2006 case report in The Lancet describing the death of a 13-day-old infant from morphine overdose to which he was allegedly exposed via breast milk. The authors claimed that maternal ultrarapid cytochrome P450 2D6 (CYP2D6) metabolism converted standard postpartum codeine doses into a lethal concentration of morphine, which passed to the infant via breast milk.In response, clinical practice pivoted away from codeine toward higher-potency opioids such as oxycodone, hydromorphone, and fentanyl. Other mothers were advised to avoid breastfeeding while taking codeine or endured undertreated postpartum pain.Today, November 21, 2026, The Lancet formally retracted that landmark 2006 paper following an institutional investigation that confirmed scientific data falsification - specifically, the deliberate omission of toxicological and postmortem findings consistent with direct neonatal pill ingestion rather than transmission through breast milk. Below is an elaborate chronological history of this controversy, its pharmacological deconstruction, and the clinical implications for neonatal practice.Bottom line:This 20-year-long saga has reshaped postpartum pain management and lactational pharmacology, demonstrating a defensive and conservative approach, which may have been suboptimal by pushing mothers toward stronger opioids. Following its conclusion in a retraction of the seminal "Toronto case", we are reminded that clinical decision-making should not be based on isolated cases, no matter how tragic or outstanding. Such reports may trigger the "fallacy of misleading vividness", goading clinicians into unsubstantiated practices to avoid such remote and improbable outcomes. Moving forward, neonatal and perinatal care must remain anchored in rigorous pharmacokinetic modeling, robust epidemiological cohorts, and evidence-based multimodal analgesia.** Disclaimer: this post is based on the relevant publications (see reference list in the end) and was compiled and written with the assistance of Google NotebookLM. It was then thoroughly reviewed by myself before posting. Any additions or corrections are welcome. **Chronological Timeline of Events2005 ── Infant death (Toronto) 2006 ── Landmark Lancet case published; CPJ column 2007 ── CFP article; FDA Public Health Advisory 2008 ── Bateman et al. critique in Lancet; Motherisk case-control study 2009 ── Willmann PBPK modeling; Motherisk 4-day guidelines 2010 ── Fabricated "Baby Boy Blue" vignette published in Paediatr Child Health 2011 ── Confidential review uncovers concealed 300 ng/mL codeine and stomach pill residue 2012 ── Juurlink cohort (n=7,804 mother-infant pairs) shows no codeine harm 2013 ── Kelly et al. prospective tool (PLoS ONE); EMA/PRAC pediatric restrictions 2015 ── IJOA editorial challenges "numerator of one" 2020 ── Zipursky & Juurlink publish toxicological refutation; CPJ & CFP retract papers 2023 ── BMJ cohort (n=85,675 dyads) and Bateman/Hale editorial confirm relative infant safety 2026 ── New Yorker exposé; 123 CPS case disclaimers; Lancet Expression of Concern (Feb); Formal Retraction of Lancet paper (Nov 21) Detailed Chronological Development1. The Incident and the Original Report (April 2005 – August 2006)April 2005: In Toronto, Ontario, a healthy, full-term, 12-day-old infant exhibited poor feeding, lethargy, and grey skin, and was pronounced dead on day 13. His mother had taken Tylenol No. 3 (acetaminophen 300 mg, codeine 30 mg, caffeine 15 mg) for episiotomy pain, 2 tablets twice daily, and from the second day onward one tablet every 6 hours. Postmortem blood testing demonstrated a markedly elevated morphine concentration of 70 ng/mL.August 2006: Dr. Gideon Koren (Director of the Motherisk Program at Toronto's Hospital for Sick Children) and colleagues (including Ontario Deputy Chief Coroner Dr. James Cairns) published the case in The Lancet:Koren G, Cairns J, Chitayat D, Gaedigk A, Leeder SJ. Pharmacogenetics of morphine poisoning in a breastfed neonate of a codeine-prescribed mother. Lancet 2006; 368(9536): 704.Genotyping revealed that the mother possessed a CYP2D6*2A allele with a CYP2D6*2x2 gene duplication (three functional copies), categorizing her as an ultrarapid metabolizer (UM). Koren posited that accelerated maternal metabolism resulted in excessive morphine excretion into breast milk (measured at 87 ng/mL in milk stored on day 10).The Omission: The paper omitted that the child's postmortem blood also contained 300 ng/mL of codeine and 5.9 µg/mL of acetaminophen, and that gastric contents contained visible white curdled material containing codeine.2. Regulatory Shockwaves and Practice Shifts (Late 2006 - 2007)Late 2006 - January 2007: Similar case accounts were published for Canadian practitioners:Madadi P, Koren G, Cairns J, et al. Maternal codeine is not safe for all breast-fed infants. Can Pharm J 2006; 139(6): 56–57.Madadi P, Koren G, Cairns J, et al. Safety of codeine during breastfeeding: fatal morphine poisoning in the breastfed neonate of a mother prescribed codeine. Can Fam Physician 2007; 53(1): 33–35.Unlike The Lancet, the Canadian columns disclosed the neonatal acetaminophen level (5.9 µg/mL), but did not highlight its toxicological incompatibility with breast milk transfer.Late 2007: Direct regulatory reaction ensued:US FDA. Public Health Advisory: Use of Codeine By Some Breastfeeding Mothers May Lead To Life-Threatening Side Effects In Nursing Babies. (December 2007).Health Canada and European authorities mirrored this advisory, leading to widespread class warnings.Clinical Practice Consequence: Obstetric units shifted away from codeine to more potent opioids such as oxycodone, hydromorphone, and fentanyl.3. Toxicological Debate and Pharmacokinetic Modeling (2008 – 2010)August 2008: Toxicologists D. Nicholas Bateman, Michael Eddleston, and Euan Sandilands challenged the biological plausibility of the report in The Lancet:Bateman DN, Eddleston M, Sandilands E. Codeine and breastfeeding. Lancet 2008; 372(9639): 625.Madadi P, Chitayat D, Koren G. Codeine and breastfeeding – Authors' reply. Lancet 2008; 372(9639): 626.Ferner RE. Did the drug cause death? Codeine and breastfeeding. Lancet 2008; 372(9639): 606–608.Bateman and colleagues calculated that even under maximal conversion, an infant consuming normal volumes of milk could not ingest a lethal morphine dose. Koren and Madadi responded by attributing the discrepant postmortem drug levels to postmortem redistribution.December 2008: Motherisk published a case-control study linking maternal codeine use to reported infant sedation:Madadi P, Ross CJ, Hayden MR, et al. Pharmacogenetics of neonatal opioid toxicity following maternal use of codeine during breastfeeding: a case-control study. Clin Pharmacol Ther 2009; 85(1): 31–35.2009: Motherisk formulated clinical guidelines:Madadi P, Moretti M, Djokanovic N, et al. Guidelines for maternal codeine use during breastfeeding. Can Fam Physician 2009; 55(11): 1077–1078.These guidelines state that:In most cases, the occurrence of CNS depression is consistent between the mother and the baby. If the mother suffers from symptoms of CNS depression (eg, somnolence, grogginess), a physician should examine the baby for signs of CNS depression as well.If the baby is not fed well, does not wake up to be fed, does not gain weight, or shows limpness, he or she should be examined by a physician.Central nervous system depression in the baby appears to worsen after 4 days, probably owing to the accumulation of morphine with more breastfeeding. If possible, codeine should not be used for longer than 4 days. If pain still necessitates codeine, an attempt should be made to decrease the dose or to switch to non-codeine painkillers (eg, NSAIDs).Women who convert more codeine to morphine have a duplication of the gene encoding for cytochrome P450 2D6. This genetic predisposition can be detected by genetic test. This test, although not available in most hospitals, is available on the market.Although codeine is widely used in North America, 9 randomized studies comparing the use of codeine with various NSAIDs in laparotomy cases (ie, abdominal surgery) failed to show codeine to be superior in pain relief.December 2009: Stefan Willmann and colleagues performed physiologically based pharmacokinetic (PBPK) modeling:Willmann S, Edginton AN, Coboeken K, Ahr G, Lippert J. Risk to the breast-fed neonate from codeine treatment to the mother: a quantitative mechanistic modeling study. Clin Pharmacol Ther 2009; 86(6): 634–643.The simulation showed that fatal neonatal morphine accumulation from breast milk was physiologically implausible unless the neonate suffered from near-total or complete cessation of renal clearance.November 2010: A case vignette featuring "Baby Boy Blue" - a neonate with lethargy, miosis, and bradypnea reportedly saved with naloxone after breast milk exposure from an ultrarapid metabolizer mother - was published:Rieder M, Koren G. Baby boy blue – why is this newborn lethargic? Paediatr Child Health 2010; 15(9): 571–572. (This case was later admitted to have been entirely fabricated, alongside 123 others):Society Note on 123 papers to add disclaimer:This is a correction to: Paediatrics & Child Health, Volume 15, Issue 9, November 2010, Pages 571–572, https://doi.org/10.1093/pch/15.9.571Disclaimer: Every clinical vignette presented within the journal's CPSP Highlights section describes a fictional case, created as a teaching tool and related to a Canadian Paediatric Surveillance Program (CPSP) study or survey.4. The Confidential Investigation and Epidemiological Studies (2010 - 2015)2010–2011: Alerted by Nick Bateman, Toronto toxicologist Dr. David Juurlink reviewed the Ontario Coroner's confidential case file. He discovered the undisclosed neonatal postmortem blood codeine level of 300 ng/mL and pathologist notes documenting white tablet residue in the infant's stomach. In November 2011, Juurlink submitted an official memorandum to the Ontario Chief Coroner, but the office declined to re-open the case.May 2012: Juurlink and colleagues published a population-based cohort study of 7,804 mother-infant dyads:Juurlink DN, Gomes T, Guttmann A, et al. Postpartum maternal codeine therapy and the risk of adverse neonatal outcomes: a retrospective cohort study. Clin Toxicol (Phila) 2012; 50(5): 390–395.Infants of mothers prescribed codeine showed no increased risk of hospital readmission (HR 0.95; 95% CI 0.81–1.11), resuscitation/ventilation, or death.July 2013: Kelly, Koren, and colleagues evaluated the 2009 guidelines in a prospective cohort of 238 mothers:Kelly LE, Chaudhry SA, Rieder MJ, et al. A Clinical Tool for Reducing Central Nervous System Depression among Neonates Exposed to Codeine through Breast Milk. PLoS ONE 2013; 8(7): e70073.Neonatal sedation was reported in 2.1% of infants, only when codeine use exceeded 4 days, with no cases in CYP2D6 UM mothers.2013: European regulatory bodies enacted broader restrictions:European Medicines Agency (EMA) / CMDh. Restrictions on use of codeine for pain relief in children – CMDh endorses PRAC recommendation. (June 2013).2015: Anaesthetists challenged the regulatory consensus:Halder S, Russell R, Quinlan J. Codeine and breast-feeding mothers. Int J Obstet Anesth 2015; 24(1): 5–7.The authors criticized national guidance (such as NICE) for basing restrictive policies on an unverified "numerator of one".5. Toxicological Refutation and Initial Retractions (2020 – 2023)May 2020: Jonathan Zipursky and David Juurlink formally published the concealed forensic evidence and toxicological analysis:Zipursky J, Juurlink DN. The Implausibility of Neonatal Opioid Toxicity from Breastfeeding. Clin Pharmacol Ther 2020; 108(5): 964–970.They demonstrated that:The infant's postmortem blood codeine level was 300 ng/mL (~50 times higher than expected from breast milk transfer).With a morphine milk concentration of 87 ng/mL, had the infant ingested 1,000 mL of milk/day (which is considerably higher than expected for an infant of similar weight), the total amount of morphine ingested via milk would have been roughly 87 µg/day, far below the standard pediatric oral therapeutic dose of ~3,200 µg/day for a 4 kg neonate.Normal hydration (the pediatrician documented weight recovery and 5 wet diapers the day before death) ruled out the severe anuria required for accumulation.November 2020: Following an invited expert peer review, Canadian journals (CPJ and CFP) issued a formal joint retraction:Tsuyuki RT, Pimlott N. Risks of maternal codeine intake in breast-fed infants: A Joint Statement of Retraction from the Canadian Pharmacists Journal and Canadian Family Physician. Can Pharm J (Ott) 2020; 154(1): 7–8 / Can Fam Physician 2020; 66(11): 793–796.March 2023: In The BMJ, Zipursky, Juurlink, and colleagues published a cohort study of 85,675 propensity-score-matched mother-infant dyads:Zipursky JS, Gomes T, Everett K, et al. Maternal opioid treatment after delivery and risk of adverse infant outcomes: population based cohort study. BMJ 2023; 380: e074005.Maternal opioid prescriptions showed no association with infant hospital readmission (HR 0.98; 95% CI 0.93-1.03), NICU admission (HR 1.12; 95% CI 0.94-1.32), or assisted ventilation (HR 0.87; 95% CI 0.60-1.26), with zero deaths. Infants of mothers prescribed codeine were significantly less likely to require readmission (HR 0.74; 95% CI 0.66-0.83), which may reflect residual confounding and should not necessarily be viewed as a protective effect.An editorial accompanying the abovementioned stated that: "The relative infant dose (bioavailability (in mg/kg) in the infant expressed as a percentage of bioavailability in the mother) is rarely >10%, indicating that both clinical effects and toxicity are unlikely. The relative infant dose for codeine, for example, is 0.6-8.1%. Subsequent effects in infants depend on metabolism that may activate or eliminate the drug. Although enzymes that metabolise drugs may not be fully developed in premature infants, toxicity is generally unlikely as relative infant doses are so low."Bateman DN, Hale TW. Opioid analgesia for breastfeeding mothers: New study reports reassuring evidence on safety for infants. BMJ 2023; 380: p514.6. The New Yorker Exposé and Retraction of The Lancet Paper (2026)January 2026: Ben Taub published an investigative exposé:Taub B. Did a Celebrated Researcher Obscure a Baby's Poisoning? The New Yorker (January 26, 2026).The article revealed that Parvaz Madadi was listed on drafts she had never seen, that Koren privately claimed the infant's stomach contained morphine to negate direct pill administration, and that Michael Rieder acknowledged the 2010 "Baby Boy Blue" case was fabricated.January – March 2026:Parvaz Madadi wrote to The Lancet on January 20, 2026, requesting retraction due to data falsification (as reported in the BMJ News: Dyer O. Breastfeeding and codeine guidance in doubt after calls for retraction of pivotal Lancet study BMJ 2026; 392 :s498 doi:10.1136/bmj.s498).Paediatrics & Child Health issued blanket disclaimers on 123 papers (including "Baby Boy Blue"), clarifying they were fictional vignettes.The Lancet editors publish an official expression of concern: Expression of Concern: Pharmacogenetics of morphine poisoning in a breastfed neonate of a codeine-prescribed mother. Lancet 2026; 407(10528): 659.May 2026:Dr. Michael Rieder published a briefing paper debating neonatal pharmacokinetics and acknowledging the rarity of potential lethal exposure to morphine via breast milk, while maintaining that such cases can occur and that clinicians need to be aware of this.He also states that: "Short courses of codeine therapy (less than 3 days) are likely to be safe, while consideration should be made for the use of alternate therapy should longer term therapy be necessary."Rieder M. Codeine toxicity via breast Milk: Can this occur and implications for opiate therapy in children. Br J Clin Pharmacol 2026; 92(9): 3012–3016.November 21, 2026: The Research Integrity Office of The Hospital for Sick Children, Toronto, Canada concluded that omitting the infant's blood codeine, blood acetaminophen, and gastric codeine findings from the original case report constituted scientific falsification, prompting formal retraction by the Lancet:The Editors of The Lancet. Retraction: Pharmacogenetics of morphine poisoning in a breastfed neonate of a codeine-prescribed mother. Lancet 2026; 408: 1812.Springer Publishing / DailyNurse. Codeine and Breastfeeding: What Clinicians Need to Know After the Lancet Retraction. (November 2026).Forensic and Pharmacokinetic ComparisonThe following table contrasts the incomplete data published in The Lancet (2006) with the full forensic profile established by postmortem toxicology and re-investigation:Analytical ParameterAs Reported in The Lancet (2006)Complete Postmortem Findings (Zipursky & Juurlink, 2020)Neonatal Pharmacological SignificancePostmortem Blood Morphine70 ng/mL70 ng/mLNormal therapeutic analgesic plasma concentrations in neonates receiving IV morphine are 10-15 ng/mL; 70 ng/mL is potentially lethal.Postmortem Blood CodeineNot reported (omitted)300 ng/mL~50 times higher than peak neonatal levels from breast milk (~2.2 ng/mL); indicates massive direct ingestion of codeine.Postmortem Blood AcetaminophenNot reported (omitted)5.9 µg/mLIncompatible with milk transfer; acetaminophen has minimal postmortem redistribution.Gastric ContentsNot reported (omitted)Curdled white material containing codeineDirect physical evidence of crushed tablet administration into the stomach.Maternal Breast Milk Morphine87 ng/mL (stored day 10)87 ng/mLAt 87 ng/mL, consuming 1,000 mL/day provides only 87 µg/day of morphine.Relative Infant Dose (RID) - MorphineNot calculated<1.2%Standard pediatric safety cutoff is <10%. Normal neonatal oral therapeutic dosing is up to 3,200 µg/day.Renal Function StatusPresumed "immature"Normal hydration and urine outputPediatrician documented birth weight recovery and 5 wet diapers the day before death, refuting the anuric accumulation required by PBPK models.Key Takeaways for Neonatal and NICU PracticeLactational Opioid Transfer is Naturally Constrained: All opioids transfer into mature breast milk in small quantities. Standard therapeutic maternal doses yield an RID well below the 10% threshold. Fatal neonatal accumulation is highly unlikely via breast milk in a thriving infant with preserved renal clearance. For premature or otherwise ill neonates, an individualized decision-making process and monitoring scheme should be undertaken.Beware the Substitution of Riskier Alternatives: Replacing codeine with high-potency opioids (oxycodone, hydromorphone, fentanyl) increases maternal dependence liability, diversion hazards, and potential neonatal adverse effects.Current Standard of Care (Stepwise Multimodal Analgesia): Postpartum pain should be managed with scheduled non-opioids (ibuprofen and acetaminophen) as the foundational tier. If breakthrough opioids are required, short courses (≤3-4 days) should be used. Mothers should be educated to monitor for extreme somnolence in themselves and poor latch, feeding difficulties, or limpness in their infants.ReferencesBateman DN, Eddleston M, Sandilands E. Codeine and breastfeeding. Lancet 2008; 372(9639): 625.Bateman DN, Hale TW. Opioid analgesia for breastfeeding mothers: New study reports reassuring evidence on safety for infants. BMJ 2023; 380: p514.Canadian Paediatric Society. Society note on 123 papers to add disclaimer. Paediatr Child Health 2026.Dyer O. Breastfeeding and codeine guidance in doubt after calls for retraction of pivotal Lancet study. BMJ 2026; 392: s498.European Medicines Agency (EMA) / CMDh. Restrictions on use of codeine for pain relief in children – CMDh endorses PRAC recommendation. 2013.Ferner RE. Did the drug cause death? Codeine and breastfeeding. Lancet 2008; 372(9639): 606–608.Halder S, Russell R, Quinlan J. Codeine and breast-feeding mothers. Int J Obstet Anesth 2015; 24(1): 5–7.Juurlink DN, Gomes T, Guttmann A, et al. Postpartum maternal codeine therapy and the risk of adverse neonatal outcomes: a retrospective cohort study. Clin Toxicol (Phila) 2012; 50(5): 390–395.Kelly LE, Chaudhry SA, Rieder MJ, et al. A Clinical Tool for Reducing Central Nervous System Depression among Neonates Exposed to Codeine through Breast Milk. PLoS ONE 2013; 8(7): e70073.Koren G, Cairns J, Chitayat D, Gaedigk A, Leeder SJ. Pharmacogenetics of morphine poisoning in a breastfed neonate of a codeine-prescribed mother. Lancet 2006; 368(9536): 704. [RETRACTED]Madadi P, Koren G, Cairns J, et al. Maternal codeine is not safe for all breast-fed infants. Can Pharm J 2006; 139(6): 56–57. [RETRACTED]Madadi P, Koren G, Cairns J, et al. Safety of codeine during breastfeeding: fatal morphine poisoning in the breastfed neonate of a mother prescribed codeine. Can Fam Physician 2007; 53(1): 33–35. [RETRACTED]Madadi P, Chitayat D, Koren G. Codeine and breastfeeding – Authors' reply. Lancet 2008; 372(9639): 626.Madadi P, Ross CJ, Hayden MR, et al. Pharmacogenetics of neonatal opioid toxicity following maternal use of codeine during breastfeeding: a case-control study. Clin Pharmacol Ther 2009; 85(1): 31–35.Madadi P, Moretti M, Djokanovic N, et al. Guidelines for maternal codeine use during breastfeeding. Can Fam Physician 2009; 55(11): 1077–1078.Rieder M, Koren G. Baby boy blue – why is this newborn lethargic? Paediatr Child Health 2010; 15(9): 571–572.Rieder M. Codeine toxicity via breast Milk: Can this occur and implications for opiate therapy in children. Br J Clin Pharmacol 2026; 92(9): 3012–3016.Springer Publishing / DailyNurse. Codeine and Breastfeeding: What Clinicians Need to Know After the Lancet Retraction. 2026.Taub B. Did a Celebrated Researcher Obscure a Baby's Poisoning? The New Yorker (January 26, 2026).The Editors of The Lancet. Expression of Concern: Pharmacogenetics of morphine poisoning in a breastfed neonate of a codeine-prescribed mother. Lancet 2026; 407(10528): 659.The Editors of The Lancet. Retraction: Pharmacogenetics of morphine poisoning in a breastfed neonate of a codeine-prescribed mother. Lancet 2026; 408: 1812.Tsuyuki RT, Pimlott N. Risks of maternal codeine intake in breast-fed infants: A Joint Statement of Retraction from the Canadian Pharmacists Journal and Canadian Family Physician. Can Pharm J (Ott) 2020; 154(1): 7–8 / Can Fam Physician 2020; 66(11): 793–796.US Food and Drug Administration (FDA). Public Health Advisory: Use of Codeine By Some Breastfeeding Mothers May Lead To Life-Threatening Side Effects In Nursing Babies. 2007.Willmann S, Edginton AN, Coboeken K, Ahr G, Lippert J. Risk to the breast-fed neonate from codeine treatment to the mother: a quantitative mechanistic modeling study. Clin Pharmacol Ther 2009; 86(6): 634–643.Zipursky J, Juurlink DN. The Implausibility of Neonatal Opioid Toxicity from Breastfeeding. Clin Pharmacol Ther 2020; 108(5): 964–970.Zipursky JS, Gomes T, Everett K, et al. Maternal opioid treatment after delivery and risk of adverse infant outcomes: population based cohort study. BMJ 2023; 380: e074005.
To read the comments in this discussion, please log in or register. It's free and open to neonatal care professionals worldwide!